36 completed, 2 terminated, 2 withdrawn, 1 active not recruiting. 19 Phase 3, 10 Phase 4, 4 Phase 1, 3 Phase 2, 1 Not applicable.
Follow Lurasidone: new trials by email Literature Review of Lurasidone trials Research Report on Lurasidone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy Lurasidone, Placebo, Background Antidepressant Therapy - Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features | Phase 3 | Not yet recruiting | Bukwang Pharmaceutical | 364 | 2026-09-28 | 2026-09-16 |
| Sequential Multiple Assignment Randomized Trial for Bipolar Depression Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine - Bipolar I Disorder, Depression | Phase 4 | Active not recruiting | Massachusetts General Hospital | 2726 | 2024-10-01 | 2025-12-16 |
| Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar Disorder Lurasidone - Bipolar Disorder (BD) | Completed | Dong-Wook Kim | 155 | 2024-09-09 | 2026-10-05 | |
| Sleep Quality, Cognitive Performance, and Computerized Cognitive Training Lurasidone, FDA Approved antidepressant treatment - Bipolar Disorder, Major Depressive Disorder | Withdrawn | George West Mental Health Foundation d/b/a Skyland Trail | 2024-04-15 | 2025-05-04 | ||
| Lurasidone Non-Interventional Study in Schizophrenia Patients Lurasidone - Schizophrenia | Completed | Aziende Chimiche Riunite Angelini Francesco S.p.A | 61 | 2022-10-21 | 2024-08-01 | |
| Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU) Lurasidone - Schizophrenia | Phase 4 | Unknown | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 10 | 2022-01-26 | 2023-03-17 |
| The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine Lurasidone - Schizophrenia | Phase 4 | Terminated | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | 13 | 2021-12-30 | 2024-04-19 |
| Chinese Longitudinal and Systematic Study of Bioplar Disorder Escitalopram Oxalate Tablets, Quetiapine Fumarate Tablets, Lurasidone - Major Depressive Disorder, Bipolar Disorder, Mixed | Not applicable | Recruiting | First Affiliated Hospital of Zhejiang University | 10000 | 2021-11-01 | 2022-10-17 |
| The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia Lurasidone - Schizophrenia | Phase 4 | Completed | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | 200 | 2021-08-16 | 2024-04-18 |
| Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia" Lurasidone, aripiprazole, olanzapine, quetiapine or risperidone - Schizophrenia | Completed | Aziende Chimiche Riunite Angelini Francesco S.p.A | 95 | 2020-07-13 | 2023-05-06 | |
| 18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder Lurasidone - Bipolar Depression | Phase 4 | Completed | New York State Psychiatric Institute | 1 | 2019-02-07 | 2023-11-13 |
| A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication ASP4345, placebo, risperidone - Schizophrenia | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 233 | 2018-07-13 | 2024-11-12 |
| A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia DSP-1349M, placebo - Schizophrenia | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 40 | 2018-06-07 | 2020-05-08 |
| A Study of Lurasidone HCl in Subjects With Schizophrenia Lurasidone - Schizophrenia | Phase 4 | Completed | Standard Chem. & Pharm. Co., Ltd. | 54 | 2018-01-03 | 2020-02-05 |
| Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia Olanzapine, Lurasidone - Schizophrenia | Phase 4 | Completed | All India Institute of Medical Sciences, Bhubaneswar | 100 | 2017-08-25 | 2020-03-31 |
| Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients lurasidone, Placebo - Bipolar Disorder | Phase 3 | Completed | Lakshmi N Yatham | 100 | 2017-05-08 | 2025-02-14 |
| Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old Latuda (Lurasidone) - Mania, Bipolar I | Phase 4 | Withdrawn | Massachusetts General Hospital | 2017-01-01 | 2018-07-20 | |
| Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies Lithium Carbonate, Lamotrigine, Valproic Acid - Bipolar Disorder | Terminated | University of New Mexico | 1037352 | 2016-09-01 | 2024-03-12 | |
| Lurasidone and Cognition in Bipolar I Disorder Lurasidone - Bipolar I Disorder | Phase 3 | Completed | University of British Columbia | 53 | 2014-05-01 | 2017-02-02 |
| Lurasidone Pediatric Bipolar Study Lurasidone, Placebo - Bipolar I Depression | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 350 | 2014-03-01 | 2017-12-20 |
Showing 20 of 44. Sign in to see all of them.
Schizophrenia (22) · Bipolar Disorder (16) · Depression (5) · Depressive Disorder, Major (4) · Autistic Disorder (3) · Psychotic Disorders (2) · Adenoviridae Infections (1) · Anxiety Disorders (1) · Arrhythmias, Cardiac (1) · Bradycardia (1) · Central Nervous System Infections (1) · Cytomegalovirus Retinitis (1) · Endocarditis (1) · Epilepsy (1) · Headache (1)
Sumitomo Pharma America, Inc. (21) · Aziende Chimiche Riunite Angelini Francesco S.p.A (2) · Marubeni Pharmaceuticals (Suzhou) Co., Ltd. (2) · Massachusetts General Hospital (2) · All India Institute of Medical Sciences, Bhubaneswar (1) · Astellas Pharma Global Development, Inc. (1) · Bukwang Pharmaceutical (1) · Daniel Benjamin (1) · Dong-Wook Kim (1) · First Affiliated Hospital of Zhejiang University (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · George West Mental Health Foundation d/b/a Skyland Trail (1) · Lakshmi N Yatham (1) · New York State Psychiatric Institute (1) · Northwestern University (1)
United States (30) · Russia (11) · Slovakia (9) · Ukraine (9) · France (8) · Canada (7) · India (7) · Colombia (6) · Czechia (6) · Japan (6) · Serbia (6) · Italy (5) · Lithuania (5) · Romania (5) · South Africa (5)
Ben W Hunter, MD (1) · Carol A Tamminga, M.D. (1) · Chi Hornik, PharmD (1) · Christophe G Lambert, PhD (1) · Debasish Hota, MD, DM (1) · Dong-Wook Kim, M.D. (1) · Herbert Meltzer, MD (1) · Janet Wozniak, M.D. (1) · John Bohn, MD (1) · Lakshmi N Yatham, MBBS,FRCPC,MRCPsych (UK),MB (1)
PMID 24955752, PMID 34751928, PMID 39144777, PMID 11383973, PMID 16829550, PMID 17006758, PMID 17159456, PMID 17459549, PMID 18791076, PMID 19497249, PMID 20218790, PMID 20568658, PMID 21357874, PMID 21639796, PMID 23415311, PMID 23541189, PMID 24035633, PMID 24170180, PMID 24330860, PMID 24595507, PMID 24614374, PMID 24949994, PMID 25681004, PMID 25844756, PMID 26039810, PMID 26117157, PMID 26363720, PMID 26521019, PMID 26631428, PMID 26730454, PMID 26908089, PMID 26926644, PMID 27089521, PMID 27215976, PMID 27454547, PMID 27522443, PMID 27529375, PMID 28137820, PMID 28185899, PMID 28290120, PMID 28779462, PMID 28901625, PMID 29084742, PMID 29146409, PMID 29173735, PMID 29271816, PMID 29435949, PMID 29677389, PMID 29920885, PMID 29943445